Organigram Global Inc. (NASDAQ:OGI) is among the 7 Best Cannabis Stocks to Invest In Now. Organigram Global Inc. (OGI) Reports Q1 Revenue of $97.3 Million, with a Consensus of $73.15 Million Organigram Global Inc. (NASDAQ:OGI) reported Q1 revenue of $97.3 million, exceeding the $73.15 million consensus, based on a February 10, 2026, TheFly report. Adjusted EBITDA was $5.3 million, up from $1.4 million in the previous year. The corporation reported higher profits and solid revenue growth over the previous ...

420 Investor launched in 2013, just ahead of Colorado legalizing for adult-use. We have moved the service to Seeking Alpha. Historically, we have provided great coverage of the sector with model portfolios, videos and written material to help investors learn about cannabis stocks, and we are excited to be doing it here!In November, I upgraded Organigram Global Inc . ( OGI ) from Hold to Buy and downgraded Village Farms ( VFF ) from Sell to Strong Sell. 12 weeks later, both stocks are down, and I am upgradin ...

Financial Data and Key Metrics Changes - In Q1, net revenue increased by 49% to CAD 65.3 million from CAD 42.7 million in the same prior year period, primarily due to growth in the Canadian business, integration of Motif, and higher international sales [17] - Adjusted gross profit for the quarter increased by 67% to CAD 23.9 million compared to CAD 14.3 million in Q1 last year, supported by higher revenue and efficiency gains [17][18] - Adjusted EBITDA in Q1 was CAD 5.3 million, up 273% from CAD 1.4 million in the prior year period, driven by increased scale and higher international sales [20][21] - Net income for the quarter was CAD 20 million compared to a net loss of CAD 23 million in the same prior year period, reflecting a CAD 43 million year-over-year improvement [21][22] Business Line Data and Key Metrics Changes - In Q1, the company harvested over 28,000 kilograms of flower, representing a 43% year-over-year increase, driven by improving yields and ongoing refinements to nutrient programs [10] - The company maintained the number one position in overall vapes with a 20.4% market share and moved to the number two position in overall pre-rolls at 7.7% [8] - In beverages, market share increased by 80 basis points year-over-year to 5.9%, while in concentrates, the company achieved a 15.5% category share [8][9] Market Data and Key Metrics Changes - The company holds the number one market share position in Canada with 11.3% total share in Q1 and 11.7% over the past 12 months [5][6] - In Quebec, the company moved up to the number three position with 9.9% market share for the quarter, driven by the success of vape launches [7] - The company outperformed in most provinces, holding 33.1% market share in New Brunswick and 21.9% in Newfoundland [8] Company Strategy and Development Direction - The company is focused on operational execution, improving margins, and delivering to markets while also looking at future international expansion opportunities [29][30] - The company aims to balance risk and growth opportunities in international markets while maintaining a strong focus on consumer needs and innovation [30] - The company is optimistic about long-term growth in the cannabis industry and its ability to compete and lead as the market matures [5] Management's Comments on Operating Environment and Future Outlook - Management noted that Q1 results reflected strong year-over-year revenue and adjusted EBITDA growth, despite seasonal resets and operational pressures [16] - The company remains confident in its ability to deliver against full-year guidance of revenue exceeding CAD 300 million, supported by improving fundamentals and expanding margins [24] - Management expressed optimism about international sales growth in fiscal 2026, despite a temporary decline in international volumes due to product specifications [12][13] Other Important Information - The company announced a proprietary breakthrough in powdery mildew resistance, allowing for early screening of seedlings and reducing crop loss [11] - The company completed commissioning of its beverage line and began in-house production to support portfolio expansion [12] - The company is preparing for EU GMP certification and is working closely with regulators to address feedback received [13][48] Q&A Session Summary Question: Near-term opportunities and long-term initiatives - Management emphasized the importance of operational execution and cost management as short-term priorities, while focusing on international expansion as a long-term goal [29][30] Question: Insight on international volumes and flower issues - Management acknowledged stringent international flower requirements and identified core drivers of recent issues, expecting to resolve them soon [35] - The estimated impact of the flower issues was approximately CAD 3.5 million on international revenue [36] Question: Recovery in the Canadian market - Management confirmed that distribution levels in BC have returned to normal and expressed confidence in recovering market share despite increased competition [42] Question: EU GMP certification timeline - Management stated they are working closely with regulators to address questions and are aiming for the fastest resolution possible, but could not provide a specific timeline [48] Question: Route to market in Europe - Management indicated a mixed approach for market entry, utilizing both direct sales and partnerships depending on regulations and market conditions [52] Question: U.S. market strategy and regulatory environment - Management noted that the U.S. market is currently a small part of their business and emphasized a cautious approach to investments due to regulatory uncertainties [55][56] Question: Increased competition in pre-rolls - Management acknowledged competitive pressures across all categories, particularly in pre-rolls and vapes, and highlighted upcoming product innovations to address these challenges [60]

Financial Data and Key Metrics Changes - In Q1, net revenue increased by 49% to CAD 65.3 million from CAD 42.7 million in the same prior year period, primarily due to growth in the Canadian business, integration of Motif, and higher international sales [17] - Adjusted gross profit for the quarter increased by 67% to CAD 23.9 million compared to CAD 14.3 million in Q1 last year, supported by higher revenue and efficiency gains [17][18] - Adjusted EBITDA in Q1 was CAD 5.3 million, up 273% from CAD 1.4 million in the prior year period, driven by increased scale and higher international sales [20][21] - Net income for the quarter was CAD 20 million compared to a net loss of CAD 23 million in the same prior year period, reflecting a CAD 43 million year-over-year improvement [21][22] Business Line Data and Key Metrics Changes - In Q1, international sales reached CAD 5 million, up 55% from Q1 fiscal 2025, despite a sequential decline due to a higher-than-expected proportion of flower that did not meet international specifications [12][17] - The company maintained the number one position in overall vapes with a 20.4% market share and moved to the number two position in overall pre-rolls at 7.7% [8][10] - In beverages, market share increased by 80 basis points year-over-year to 5.9%, while in concentrates, the company achieved a 15.5% category share [8][10] Market Data and Key Metrics Changes - The company holds the number one market share position in Canada with 11.3% total share in Q1 and 11.7% over the past 12 months [5][6] - In Quebec, the company moved up to the number three position with 9.9% market share for the quarter, driven by successful vape launches [7] - The company outperformed in most provinces, holding 33.1% market share in New Brunswick and 21.9% in Newfoundland [8] Company Strategy and Development Direction - The company is focused on operational execution, improving margins, and delivering to markets while balancing risk and growth opportunities in international markets [29][30] - The company aims to expand into international markets prudently while maintaining a strong focus on consumer needs and innovation [30][31] - The company is optimistic about long-term growth in the cannabis industry and its ability to compete and lead as the market matures [5] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the impact of the BC General Employees' Union strike and increased competition in vapes and pre-rolls on market share [6][15] - The company remains confident in its ability to deliver against previously issued guidance, expecting revenue to exceed CAD 300 million for the full year [24] - Management expressed optimism about international sales growth in fiscal 2026, despite temporary issues with product specifications [12][13] Other Important Information - The company harvested over 28,000 kilograms of flower in Q1, representing a 43% year-over-year increase, driven by improved yields and ongoing refinements [10] - The company announced a proprietary breakthrough in powdery mildew resistance, allowing for quicker screening of seedlings [11] - Total cash and short-term investments at quarter end were CAD 63 million, including CAD 7.6 million of unrestricted cash [23] Q&A Session Summary Question: Near-term opportunities and prioritization of initiatives - Management emphasized operational execution and cost base improvement as short-term priorities, while focusing on international expansion for long-term growth [29][30] Question: Insight on international volumes and flower issues - Management noted stringent international flower requirements and identified core drivers of recent issues, expecting to resolve them soon [35] - The estimated impact on international revenue was about CAD 3.5 million due to out-of-spec flower [36] Question: Recovery in the Canadian market - Management confirmed recovery in BC distribution levels and acknowledged increased competition in vapes and pre-rolls, with plans for new innovations to regain market share [42][43] Question: EU GMP certification timeline - Management is working closely with regulators to address feedback and is unable to provide a specific timeline for certification [47][48] Question: Route to market in Europe - Management indicated a mixed approach for market entry, utilizing both direct sales and partnerships depending on regulations [51][53] Question: U.S. market investment strategy - Management stated that the U.S. market is currently a minor part of the business, and they are being cautious with investments due to regulatory uncertainties [55][56]

OrganiGram (NasdaqGS:OGI) Q1 2026 Earnings call February 10, 2026 08:00 AM ET Speaker6I will now hand the call over to Max Schwartz, Director of Investor Relations. Please go ahead.Speaker5Very much, Kara. Good morning, everyone. Thanks for joining us today. As a brief reminder, this call is being recorded, and a replay will be available on our website within 24 hours. Today's call will include forward-looking information, forward-looking statements, and actual results could differ materially due to a numbe ...

Investor Presentation December 31, 2025 CAUTIONARY STATEMENT This document is current as of December 31, 2025, except where otherwise stated. The information contained in this presentation is provided by Organigram Global Inc. ("Organigram" or the "Company") for informational purposes only and does not constitute an offer to issue or arrange to issue, or the solicitation of an offer to issue, securities of Organigram or other financial products. No part of this presentation shall form the basis or be relied ...

Organigram Reports First Quarter Fiscal 2026 ResultsFeb 10, 2026 6:00 AM Eastern Standard Time# Organigram Reports First Quarter Fiscal 2026 ResultsShare---Strong year-over-year growth supported by Canadian leadership and growing international sales, improving gross margin.TORONTO--([BUSINESS WIRE])--Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the "Company†or "Organigram†), Canada's #1 cannabis company by market share1, is pleased to announce its results for the first quarter ended December 31, 2025 ...

TORONTO--(BUSINESS WIRE)--Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the "Company†or "Organigram†), Canada's #1 cannabis company by market share, announced today it will report earnings results for its first quarter fiscal 2026 ended December 31, 2025, on Tuesday, February 10, 2026, prior to market open. The Company will host a conference call to discuss its results with details as follows: Date: Tuesday, February 10, 2026 Time: 8:00 am Eastern Time To register for the conference call,. ...

Core Viewpoint - Organigram Global Inc. has announced an expansion of its innovation investment in Phylos Bioscience Inc., reinforcing its leadership in seed-based cannabis genetics [1] Group 1: Company Developments - Organigram is recognized as Canada's 1 cannabis company by market share [1] - The company has secured priority access to Phylos' autoflower genetics pipeline through an amended loan and product agreement [1] - The new agreement includes preferential economic terms and long-term benefits for Organigram [1]

Core Viewpoint - Organigram Global Inc. (OGI) has shown robust growth and operating leverage, leading to margin expansion, which justifies a buy rating initiated last August. The stock has increased by 31% since the rating due to solid Q4 performance [1]. Company Analysis - The company has demonstrated strong growth metrics, contributing to a favorable investment outlook. The increase in stock price reflects positive market sentiment and operational efficiency [1]. Market Trends - The analysis highlights the importance of thorough research and understanding of financial statements and market trends, which are critical for identifying undervalued investment opportunities in mid and small-cap companies [1].